Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 7.75 USD 1.04% Market Closed
Market Cap: 1.2B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+20%
Revenue
Forecast
+8%
Net Income
Forecast
+10%

Wall Street
Price Targets

OCUL Price Targets Summary
Ocular Therapeutix Inc

Wall Street analysts forecast OCUL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OCUL is 17.85 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

OCUL Lowest Forecast
Wall Street Target
14.14 USD
82% Upside
OCUL Average Forecast
Wall Street Target
17.85 USD
130% Upside
OCUL Highest Forecast
Wall Street Target
23.1 USD
198% Upside
Lowest
Price Target
14.14 USD
82% Upside
Average
Price Target
17.85 USD
130% Upside
Highest
Price Target
23.1 USD
198% Upside
Ocular Therapeutix Inc Competitors:
Price Targets
M
MEGA
Mega Lifesciences PCL
27% Upside
CRON
Cronos Group Inc
43% Upside
4536
Santen Pharmaceutical Co Ltd
42% Upside
J
600380
Joincare Pharmaceutical Group Industry Co Ltd
20% Upside
M
MEGA
Mega Lifesciences PCL
27% Upside
CRON
Cronos Group Inc
43% Upside
4536
Santen Pharmaceutical Co Ltd
42% Upside
J
600380
Joincare Pharmaceutical Group Industry Co Ltd
20% Upside
1477
Ocumension Therapeutics
51% Upside
VIRP
Virbac SA
31% Upside
LUPIN
Lupin Ltd
15% Upside
CORT
Corcept Therapeutics Inc
86% Upside

Revenue
Forecast

Revenue Estimate
Ocular Therapeutix Inc

For the last 8 years the compound annual growth rate for Ocular Therapeutix Inc's revenue is 55%. The projected CAGR for the next 3 years is 37%.

55%
Past Growth
37%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ocular Therapeutix Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ocular Therapeutix Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-70%
Average Miss
What are analyst estimates?

See Also

Summary
OCUL intrinsic value, competitors valuation, and company profile.
DCF Valuation
OCUL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OCUL stock valuation using valuation multiples.
Wall Street Estimates
OCUL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OCUL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OCUL's stock price target?
Price Target
17.85 USD

According to Wall Street analysts, the average 1-year price target for OCUL is 17.85 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

What is Ocular Therapeutix Inc's Revenue forecast?
Projected CAGR
37%

For the last 8 years the compound annual growth rate for Ocular Therapeutix Inc's revenue is 55%. The projected CAGR for the next 3 years is 37%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.